Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation

6th January 2026 Uncategorised 0

First‑in‑class SK ion channel inhibitor enters next stage of clinical development

More: Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
Source: News